N/A
Completed N=128
Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal
Respiratory Complication
Source: ClinicalTrials.gov NCT01915108 ↗
Enrolled (actual)
128
Serious AEs
1.7%
Results posted
Aug 2014
Primary outcomePrimary: Number of Patients With Adverse Events Following LMA Removal — 10; 5; 1; 0 participants
Summary
This study was designed to determine the optimal dose of remifentanil that can prevent the complications associated with the removal of LMA without delaying emergence.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With Adverse Events Following LMA Removal |
10; 5; 1; 0 | — |
Eligibility Criteria
Inclusion Criteria
- American Society of Anesthesiologists physical status 1 or 2
- undergoing lower extremity surgery under general anesthesia
Exclusion Criteria
- suspected difficult airways
- respiratory disease (chronic obstructive pulmonary disease, upper respiratory infection)
- body mass index > 30 kg/m2
- allergies to the study drugs
- a history of gastric reflux
Data sourced from ClinicalTrials.gov (NCT01915108). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.